Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

OBN Science Social

OBN's Science Social event offers a fantastic opportunity for professionals in the life sciences sector to connect and build relationships in a relaxed, informal setting. [...]

Go to Top